Ocular Therapeutix announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration, or wet AMD. OTX-TKI is also being developed for the treatment of diabetic retinopathy and other retinal diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCUL:
- Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
- AffaMed announces first patient treated in Phase study of DEXTENZA
- Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
- Ocular Therapeutix reports Q2 EPS (26c), consensus (30c)
- Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update